Epilepsy Nervous System Diseases Epilepsy
Conditions
Interventions
Following baseline recording of seizure frequency participants will be randomly assigned to one of two arms:
CBT (plus standard medical care):
CBT will comprise 12 wee
Sponsors
Institute of Psychiatry, King's College London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, age 18-65 years 2. Clinical diagnosis (with supporting electroencephalography [EEG]) of epilepsy 3. A maximum of 40 seizures/month involving alteration/loss of consciousness (i.e. complex partial or generalised seizures) with no limit to simple partial seizure frequency 4. Stable medication for the month prior to recruitment 5. Able to attend weekly/fortnightly sessions 6. Willing to complete questionnaires regularly to monitor progress
Exclusion criteria
Exclusion criteria: 1. History of, or current actual/suspected non-epileptic seizures 2. <2 seizures per month in each of the preceding four months 3. Active major psychiatric disorder 4. Drug/alcohol dependence 5. Receiving active vagus nerve stimulation (VNS) for seizures that has been adjusted within the previous 12 months 6. Insufficiently fluent in English to be able to undertake treatment and complete questionnaires without the assistance of an interpreter 7. Established learning disability (or where this has been measured formally, IQ <70)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Monthly seizure frequency, monitored throughout the study. Total duration of follow-up: 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Liverpool Seizure Severity Scale at baseline, 8 and 12 weeks 2. Hospital Anxiety and Depression Scale at baseline, 8 and 12 weeks 3. Quality of Life in Epilepsy Inventory-31 (QOLIE-31) at baseline, 8 and 12 weeks 4. Health service usage for previous 8 weeks, assessed using the Client Service Receipt Inventory (CSRI) at baseline, beginning of treatment, 8-week follow-up and for previous 4 weeks at 12 week follow up 5. Health status, assessed by Euroqol EQ-5D at baseline, 8 and 12 weeks | — |
Countries
United Kingdom
Outcome results
None listed